Acute regulation of mouse AE2 anion exchanger requires isoform-specific amino acid residues from most of the transmembrane domain.
The widely expressed anion exchanger polypeptide AE2/SLC4A2 is acutely inhibited by acidic intracellular (pH(i)), by acidic extracellular pH (pH(o)), and by the calmodulin inhibitor, calmidazolium, whereas it is acutely activated by NH(4)(+). The homologous erythroid/kidney AE1/SLC4A1 polypeptide is insensitive to these regulators. Each of these AE2 regulatory responses requires the presence of AE2's C-terminal transmembrane domain (TMD). We have now measured (36)Cl(-) efflux from Xenopus oocytes expressing bi- or tripartite AE2-AE1 chimeras to define TMD subregions in which AE2-specific sequences contribute to acute regulation. The chimeric AE polypeptides were all functional at pH(o) 7.4, with the sole exception of AE2((1-920))/AE1((613-811))/AE2((1120-1237)). Reciprocal exchanges of the large third extracellular loops were without effect. AE2 regulation by pH(i), pH(o) and NH(4)(+) was retained after substitution of C-terminal AE2 amino acids 1120-1237 (including the putative second re-entrant loop, two TM spans and the cytoplasmic tail) with the corresponding AE1 sequence. In contrast, the presence of this AE2 C-terminal sequence was both necessary and sufficient for inhibition by calmidazolium. All other tested TMD substitutions abolished AE2 pH(i) sensitivity, abolished or severely attenuated sensitivity to pH(o) and removed sensitivity to NH(4)(+). Loss of AE2 pH(i) sensitivity was not rescued by co-expression of a complementary AE2 sequence within separate full-length chimeras or AE2 subdomains. Thus, normal regulation of AE2 by pH and other ligands requires AE2-specific sequence from most regions of the AE2 TMD, with the exceptions of the third extracellular loop and a short C-terminal sequence. We conclude that the individual TMD amino acid residues previously identified as influencing acute regulation of AE2 exert that influence within a regulatory structure requiring essential contributions from multiple regions of the AE2 TMD.
Stewart
A K
AK
Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Kurschat
C E
CE
Vaughan-Jones
R D
RD
Shmukler
B E
BE
Alper
S L
SL
D000595:Amino Acid Sequence; D000818:Animals; D001457:Anion Exchange Protein 1, Erythrocyte / Q000378:metabolism; D027321:Anion Transport Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D017920:Antiporters / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D027963:Chloride-Bicarbonate Antiporters; D018389:Codon, Nonsense; D005260:Female; D006863:Hydrogen-Ion Concentration; D007093:Imidazoles / Q000494:pharmacology*; D051379:Mice; D009865:Oocytes / Q000378:metabolism; D010455:Peptides / Q000378:metabolism; D020033:Protein Isoforms / Q000378:metabolism; D017434:Protein Structure, Tertiary; D000644:Quaternary Ammonium Compounds / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D064606:SLC4A Proteins; D014982:Xenopus laevis
D001457:Anion Exchange Protein 1, Erythrocyte; D027321:Anion Transport Proteins; D017920:Antiporters; D027963:Chloride-Bicarbonate Antiporters; D018389:Codon, Nonsense; D007093:Imidazoles; D010455:Peptides; D020033:Protein Isoforms; D000644:Quaternary Ammonium Compounds; D011993:Recombinant Fusion Proteins; D064606:SLC4A Proteins; C579495:Slc4a2 protein, mouse; C031938:calmidazolium
Pflugers Arch. 2004 Feb;447(5):495-509
14722772
J Biol Chem. 2003 Nov 7;278(45):44949-58
12933803
Blood Cells Mol Dis. 2004 May-Jun;32(3):379-83
15121095
J Biol Chem. 2004 May 28;279(22):23565-73
15044489
Biochim Biophys Acta. 2004 Jul 1;1664(1):80-7
15238261
J Biol Chem. 2004 Sep 10;279(37):38544-54
15234974
Biochim Biophys Acta. 1978 Feb 21;507(2):294-304
626736
J Biol Chem. 1989 May 15;264(14):7784-7
2542243
Proc Natl Acad Sci U S A. 1989 Jul;86(14):5429-33
2526338
Cell. 1989 Dec 1;59(5):927-37
2686841
Proc Natl Acad Sci U S A. 1990 Jul;87(14):5278-82
2371270
Annu Rev Physiol. 1991;53:549-64
2042971
J Biol Chem. 1991 Aug 25;266(24):15726-37
1874731
Biochemistry. 1995 Mar 21;34(11):3588-95
7893655
Biochemistry. 1995 Jul 25;34(29):9315-24
7626600
J Biol Chem. 1996 Mar 8;271(10):5741-9
8621440
J Gen Physiol. 1997 Mar;109(3):345-60
9089441
Am J Physiol. 1997 Apr;272(4 Pt 1):C1232-40
9142848
J Biol Chem. 1999 Mar 5;274(10):6626-33
10037758
Biochemistry. 1999 Jun 29;38(26):8521-31
10387099
J Biol Chem. 2004 Dec 10;279(50):52664-76
15452108
FEBS J. 2005 Apr;272(7):1625-38
15794750
Traffic. 2006 Feb;7(2):117-28
16420521
J Biol Chem. 2006 Jan 27;281(4):1885-96
16286476
J Physiol. 2007 Jan 1;578(Pt 1):131-42
17038436
Am J Physiol Cell Physiol. 2007 Feb;292(2):C909-18
17005605
J Biol Chem. 2007 Mar 16;282(11):8474-86
17227773
J Biol Chem. 2007 May 4;282(18):13402-9
17353191
Pflugers Arch. 2007 Jun;454(3):373-84
17492309
Mol Biol Cell. 2002 Dec;13(12):4371-87
12475959
Biochem J. 1999 Dec 15;344 Pt 3:699-711
10585856
Biochemistry. 2000 May 9;39(18):5527-33
10820026
Biochemistry. 2000 Nov 7;39(44):13344-9
11063570
Am J Physiol Cell Physiol. 2001 Oct;281(4):C1344-54
11546673
Biochem J. 2001 Nov 1;359(Pt 3):661-8
11672441
Annu Rev Physiol. 2002;64:899-923
11826292
Biochemistry. 2002 Mar 12;41(10):3311-20
11876639
Am J Physiol Renal Physiol. 2002 May;282(5):F810-20
11934690
J Biol Chem. 2002 Sep 27;277(39):36706-14
12151412
J Gen Physiol. 2002 Nov;120(5):707-22
12407081
Biochemistry. 2002 Nov 26;41(47):13973-81
12437354
J Biol Chem. 2003 Jan 31;278(5):3112-20
12446737
Am J Physiol Cell Physiol. 2003 May;284(5):C1235-46
12529246
Biochem J. 2003 May 1;371(Pt 3):687-96
12578559
Am J Physiol Renal Physiol. 2003 Jun;284(6):F1199-206
12604466
J Biol Chem. 2004 Apr 9;279(15):14961-6
14749323